Biovail acquisition of Wellbutrin XL cleared in USA

Canada's Biovail Corp says that the waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act has expired with respect to  the acquisition of rights to Wellbutrin XL (bupropion HCl  extended-release tablets) from UK-headquartered drug giant  GlaxoSmithKline.

Under the terms of the agreement, Biovail has paid $510.0 million to GSK  to acquire the full US rights to the drug, which is indicated for the  treatment of major depressive disorder and seasonal affective disorder.